# What's Missing from ICER's Analysis of Migraine Therapies?

The Institute for Clinical and Economic Review says new CGRP inhibitor treatments for chronic and episodic migraine probably won't be cost effective. But the analysis omits five important components.

#### **Valuable Data:**

ICER chose to issue its report before long-term or real-world data were available.

### Effect on the Opioid Crisis:

ICER excludes the value that preventive migraine treatment could have on reducing opioid dependence and addiction.

## Potential Impact on Mortality:

ICER ignores research that demonstrates migraine patients' elevated risk of dying from heart problems and strokes.

#### **Full Disclosure:**

ICER withholds the data it used to calculate CGRP inhibitors' effectiveness.

### **Depression Comorbidity:**

ICER does not account for treatment's potential impact on depression, which affects nearly 80 percent of migraine patients and is a risk factor for suicide.

